Literatur zum Artikel Wintergerst

• Literatur

• 1 Ambruso DR, Knall C, Abell AN. et al. Human neutrophil immunodeficiency syndrome is associated with an inhibitory Rac2 mutation. Proc Natl Acad Sci U S A 2000; 97: 4654-4659.
• 2 Babior BM. NADPH oxidase: an update. Blood 1999; 93: 1464-1476.
• 3 Babior BM, Lambeth JD, Nauseef W. The neutrophil NADPH oxidase. Arch Biochem Biophys 2002; 397: 342-344.
• 4 Baehner RL, Johnston Jr RB, Nathan DG. Comparative study of the metabolic and bactericidal characteristics of severely glucose-6-phosphate dehydrogenase-deficient polymorphonuclear leukocytes and leukocytes from children with chronic granulomatous disease. Journal of the Reticuloendothelial Society 1972; 12: 150-169.
• 5 Baldus M, Zunftmeister V, Geibel-Werle G. et al. Chediak-Higashi-Steinbrinck syndrome (CHS) in a 27-year-old woman – effects of G-CSF treatment. Annals of hematology 1999; 78: 321-327.
• 6 Ballard R, Tien RD, Nohria V, Juel V. The Chediak- Higashi syndrome: CT and MR findings. Pediatric radiology 1994; 24: 266-267.
• 7 Bauer TJ, Allen JM, Tuschong LM. et al. Successful GeneTherapy of Canine LeukocyteAdhesion Deficiency Using Foamy Viral Vectors.. In: 10th Annual meeting of the American Society of Gene Therapy.. Seattle, Washington, USA; 2007: 305-336.
• 8 Bauer Jr TR, Hickstein DD. Gene therapy for leukocyte adhesion deficiency. Current opinion in molecular therapeutics 2000; 2: 383-388.
• 9 Bejaoui M, Veber F, Girault D. et al. [The accelerated phase of Chediak-Higashi syndrome]. Archives francaises de pediatrie 1989; 46: 733-736.
• 10 Berthet F, Siegrist CA, Ozsahin H. et al. Bone marrow transplantation in cartilage-hair hypoplasia: correction of the immunodeficiency but not of the chondrodysplasia. Eur J Pediatr 1996; 155: 286-290.
• 11 Beutler E. Red cell metabolism.. In: A manual of biochemical methods.. 3rd ed. New York: Grune and Stratton; 1984
• 12 Beutler E, Vulliamy T, Luzzatto L. Hematologically important mutations: glucose-6-phosphate dehydrogenase. Blood cells, molecules & diseases 1996; 22: 49-56.
• 13 Boxer GJ, Holmsen H, Robkin L. et al. Abnormal platelet function in Chediak-Higashi syndrome. British journal of haematology 1977; 35: 521-533.
• 14 Cesaro S, Oneto R, Messina C. et al. Haematopoietic stem cell transplantation for Shwachman-Diamond disease: a study from the European Group for blood and marrow transplantation. British journal of haematology 2005; 131: 231-236.
• 15 Chediak MM. [New leukocyte anomaly of constitutional and familial character.]. Revue d’ hematologie 1952; 7: 362-367.
• 16 Chin TW, Stiehm ER, Falloon J, Gallin JI. Corticosteroids in treatment of obstructive lesions of chronic granulomatous disease. J Pediatr 1987; 111: 349-352.
• 17 Cooper MR, DeChatelet LR, McCall CE. et al. Complete deficiency of leukocyte glucose- 6-phosphate dehydrogenase with defective bactericidal activity. The Journal of clinical investigation 1972; 51: 769-778.
• 18 Dale DC, Bolyard AA, Aprikyan A. Cyclic neutropenia. Semin Hematol 2002; 39: 89-94.
• 19 Dale DC, Person RE, Bolyard AA. et al. Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. Blood 2000; 96: 2317-2322.
• 20 Dang PM, Cross AR, Quinn MT, Babior BM. Assembly of the neutrophil respiratory burst oxidase: a direct interaction between p67PHOX and cytochrome b558 II. Proc Natl Acad Sci U S A 2002; 99: 4262-4265.
• 21 Danziger RN, Goren AT, Becker J. et al. Outpatient management with oral corticosteroid therapy for obstructive conditions in chronic granulomatous disease. J Pediatr 1993; 122: 303-305.
• 22 Devriendt K, Kim AS, Mathijs G. et al. Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nature genetics 2001; 27: 313-317.
• 23 Dinauer MC, Li LL, Bjorgvinsdottir H. et al. Longterm correction of phagocyte NADPH oxidase activity by retroviral- mediated gene transfer in murine X-linked chronic granulomatous disease. Blood 1999; 94: 914-922.
• 24 Dokal I. Dyskeratosis congenita in all its forms. British journal of haematology 2000; 110: 768-779.
• 25 Durandy A, Breton-Gorius J, Guy-Grand D. et al. Prenatal diagnosis of syndromes associating albinism and immune deficiencies (Chediak-Higashi syndrome and variant). Prenatal diagnosis 1993; 13: 13-20.
• 26 Etzioni A. Novel aspects of phagocytic cell disorders. Current opinion in allergy and clinical immunology 2001; 1: 535-540.
• 27 Etzioni A, Harlan JM, Pollack S. et al. Leukocyte adhesion deficiency (LAD) II: a new adhesion defect due to absence of sialyl Lewis X, the ligand for selectins. Immunodeficiency 1993; 4: 307-308.
• 28 Etzioni A, Tonetti M. Fucose supplementation in leukocyte adhesion deficiency type II. Blood 2000; 95: 3641-3643.
• 29 Etzioni A, Tonetti M. Leukocyte adhesion deficiency II-from A to almost Z. Immunological reviews 2000; 178: 138-147.
• 30 Finn A, Hadzic N, Morgan G, Strobel S, Levinsky RJ. Prognosis of chronic granulomatous disease. Arch Dis Child 1990; 65: 942-945.
• 31 Fischer A, Segal AW, Seger R, Weening RS. The management of chronic granulomatous disease. Eur J Pediatr 1993; 152: 896-899.
• 32 Frydman M, Etzioni A, Eidlitz-Markus T. et al. Rambam-Hasharon syndrome of psychomotor retardation, short stature, defective neutrophil motility, and Bombay phenotype. American journal of medical genetics 1992; 44: 297-302.
• 33 Fukuda M, Morimoto T, Ishida Y. et al. Improvement of peripheral neuropathy with oral prednisolone in Chediak-Higashi syndrome. Eur J Pediatr 2000; 159: 300-301.
• 34 Gallin JI. Interferon-gamma in the management of chronic granulomatous disease. Rev Infect Dis 1991; 13: 973-978.
• 35 Gallin JI, Farber JM, Holland SM, Nutman TB. Interferon- gamma in the management of infectious diseases. Ann Intern Med 1995; 123: 216-224.
• 36 Ginzberg H, Shin J, Ellis L. et al. Shwachman syndrome: phenotypic manifestations of sibling sets and isolated cases in a large patient cohort are similar. J Pediatr 1999; 135: 81-88.
• 37 Gray GR, Stamatoyannopoulos G, Naiman SC. et al. Neutrophil dysfunction, chronic granulomatous disease, and non-spherocytic haemolytic anaemia caused by complete deficiency of glucose- 6-phosphate dehydrogenase. Lancet 1973; 2: 530-534.
• 38 Greenberg DE, Porcella SF, Stock F. et al. Granulibacter bethesdensis gen. nov., sp. nov., a distinctive pathogenic acetic acid bacterium in the family Acetobacteraceae. International journal of systematic and evolutionary microbiology 2006; 56: 2609-2616.
• 39 Grez M, Becker S, Saulnier S. et al. Gene therapy of chronic granulomatous disease. Bone Marrow Transplant 2000; 25 (02) S99-104.
• 40 Gungor T, Halter J, Klink A. et al. Successful low toxicity hematopoietic stem cell transplantation for high-risk adult chronic granulomatous disease patients. Transplantation 2005; 79: 1596-1606.
• 41 Haddad E, Le Deist F, Blanche S. et al. Treatment of Chediak-Higashi syndrome by allogenic bone marrow transplantation: report of 10 cases. Blood 1995; 85: 3328-3333.
• 42 Heiss NS, Knight SW, Vulliamy TJ. et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nature genetics 1998; 19: 32-38.
• 43 Herbrecht R, Denning DW, Patterson TF. et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
• 44 Higashi O. Congenital gigantism of peroxidase granules; the first case ever reported of qualitative abnormity of peroxidase. The Tohoku journal of experimental medicine 1954; 59: 315-332.
• 45 Hof H. Intracellular microorganisms: a particular problem for chemotherapy. Introduction. Infection 1991; 19: S193-194.
• 46 Hoyeraal HM, Lamvik J, Moe PJ. Congenital hypoplastic thrombocytopenia and cerebral malformations in two brothers. Acta paediatrica Scandinavica 1970; 59: 185-191.
• 47 Hreidarsson S, Kristjansson K, Johannesson G, Johannsson JH. A syndrome of progressive pancytopenia with microcephaly, cerebellar hypoplasia and growth failure. Acta paediatrica Scandinavica 1988; 77: 773-775.
• 48 Ikinciogullari A, Dogu F, Solaz N. et al. Granulocyte transfusions in children with chronic granulomatous disease and invasive aspergillosis. Ther Apher Dial 2005; 9: 137-141.
• 49 Karim MA, Suzuki K, Fukai K. et al. Apparent genotype- phenotype correlation in childhood, adolescent, and adult Chediak-Higashi syndrome. American journal of medical genetics 2002; 108: 16-22.
• 50 Keating GM. Posaconazole. Drugs 2005; 65: 1553-1567 discussion 68-69.
• 51 Kinashi T, Aker M, Sokolovsky-Eisenberg M. et al. LAD-III, a leukocyte adhesion deficiency syndrome associated with defective Rap1 activation and impaired stabilization of integrin bonds. Blood 2004; 103: 1033-1036.
• 52 Klein C, Grudzien M, Appaswamy G. et al. HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease). Nature genetics 2007; 39: 86-92.
• 53 Lau YL, Ha SY, Chan CF. et al. Bone marrow transplant for dyskeratosis congenita. British journal of haematology 1999; 105: 571.
• 54 Lekstrom-Himes JA, Dorman SE, Kopar P. et al. Neutrophil-specific granule deficiency results from a novel mutation with loss of function of the transcription factor CCAAT/enhancer binding protein epsilon. J Exp Med 1999; 189: 1847-1852.
• 55 Liese J, Kloos S, Jendrossek V. et al. Long-term follow-up and outcome of 39 patients with chronic granulomatous disease. J Pediatr 2000; 137: 687-693.
• 56 Zeidler C, Welte K, Barak Y. et al. Stem cell transplantation in patients with severe congenital neutropenia without evidence of leukemic transformation. Blood 2000; 95: 1195-1198.
• 57 Liese JG, Jendrossek V, Jansson A. et al. Chronic granulomatous disease in adults. Lancet 1996; 347: 220-223.
• 58 Liese JG, Jendrossek V, Jansson A. et al. Chronic granulomatous disease in adults. Lancet 1996; 347: 220-223.
• 59 Lubke T, Marquardt T, Etzioni A. et al. Complementation cloning identifies CDG-IIc, a new type of congenital disorders of glycosylation, as a GDP-fucose transporter deficiency. Nature genetics 2001; 28: 73-76.
• 60 Lublin M, Bartlett DL, Danforth DN. et al. Hepatic abscess in patients with chronic granulomatous disease. Ann Surg 2002; 235: 383-391.
• 61 Luhn K, Wild MK, Eckhardt M. et al. The gene defective in leukocyte adhesion deficiency II encodes a putative GDP-fucose transporter. Nature genetics 2001; 28: 69-72.
• 62 Lun A, Roesler J, Renz H. Unusual late onset of X-linked chronic granulomatous disease in an adult woman after unsuspicious childhood. Clin Chem 2002; 48: 780-781.
• 63 Makitie O, Kaitila I. Cartilage-hair hypoplasia – clinical manifestations in 108 Finnish patients. Eur J Pediatr 1993; 152: 211-217.
• 64 Makitie O, Pukkala E, Teppo L, Kaitila I. Increased incidence of cancer in patients with cartilagehair hypoplasia. J Pediatr 1999; 134: 315-318.
• 65 Makitie O, Sulisalo T, de la Chapelle A, Kaitila I. Cartilage-hair hypoplasia. Journal of medical genetics 1995; 32: 39-43.
• 66 Malech HL, Bauer Jr TR, Hickstein DD. Prospects for gene therapy of neutrophil defects. Semin Hematol 1997; 34: 355-361.
• 67 Malech HL, Hickstein DD. Genetics, biology and clinical management of myeloid cell primary immune deficiencies: chronic granulomatous disease and leukocyte adhesion deficiency. Current opinion in hematology 2007; 14: 29-36.
• 68 Margolis DM, Melnick DA, Alling DW, Gallin JI. Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis 1990; 162: 723-726.
• 69 Marquardt T, Luhn K, Srikrishna G. et al. Correction of leukocyte adhesion deficiency type II with oral fucose. Blood 1999; 94: 3976-3985.
• 70 Metcalf SC, Dockrell DH. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts. The Journal of infection 2007; 55: 287-299.
• 71 Misra VP, King RH, Harding AE. et al. Peripheral neuropathy in the Chediak-Higashi syndrome. Acta neuropathologica 1991; 81: 354-358.
• 72 Mouy R, Fischer A, Vilmer E. et al. Incidence, severity, and prevention of infections in chronic granulomatous disease. J Pediatr 1989; 114: 555-560.
• 73 Mouy R, Fischer A, Vilmer E. et al. Incidence, severity, and prevention of infections in chronic granulomatous disease. J Pediatr 1989; 114: 555-560.
• 74 Mouy R, Veber F, Blanche S. et al. Long-term itraconazole prophylaxis against Aspergillus infections in thirty-two patients with chronic granulomatous disease. J Pediatr 1994; 125: 998-1003.
• 75 Nagle DL, Karim MA, Woolf EA. et al. Identification and mutation analysis of the complete gene for Chediak-Higashi syndrome. Nature genetics 1996; 14: 307-311.
• 76 Notheis G, Tarani L, Costantino F. et al. Posaconazole for treatment of refractory invasive fungal disease. Mycoses 2006; 49 (01) 37-41.
• 77 Nunoi H, Yamazaki T, Kanegasaki S. Neutrophil cytoskeletal disease. International journal of hematology 2001; 74: 119-124.
• 78 Nunoi H, Yamazaki T, Tsuchiya H. et al. A heterozygous mutation of beta-actin associated with neutrophil dysfunction and recurrent infection. Proc Natl Acad Sci U S A 1999; 96: 8693-8698.
• 79 Ochs HSC, Puck J. Primary Immunodeficiency diseases.. 2nd ed: Oxford: 2007
• 80 Ott MG, Schmidt M, Schwarzwaelder K. et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nature medicine 2006; 12: 401-409.
• 81 Ott MG, Seger R, Stein S. et al. Advances in the treatment of Chronic Granulomatous Disease by gene therapy. Current gene therapy 2007; 7: 155-161.
• 82 Ozsahin H, von Planta M, Muller I. et al. Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin- B. Blood 1998; 92: 2719-2724.
• 83 Pang Q, Christianson TA, Koretsky T. et al. Nucleophosmin interacts with and inhibits the catalytic function of eukaryotic initiation factor 2 kinase PKR. The Journal of biological chemistry 2003; 278: 41709-41717.
• 84 Petropoulou T, Liese J, Tintelnot K. et al. [Longterm treatment of patients with itraconazole for the prevention of Aspergillus infections in patients with chronic granulomatous disease (CGD)]. Mycoses 1994; 37: 64-69.
• 85 Rao K, Amrolia PJ, Jones A. et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 2005; 105: 879-885.
• 86 Rescigno R, Dinowitz M. Ophthalmic manifestations of immunodeficiency states. Clinical reviews in allergy & immunology 2001; 20: 163-181.
• 87 Rezaei N, Farhoudi A, Ramyar A. et al. Congenital neutropenia and primary immunodeficiency disorders: a survey of 26 Iranian patients. J Pediatr Hematol Oncol 2005; 27: 351-356.
• 88 Ridanpaa M, van Eenennaam H, Pelin K. et al. Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia. Cell 2001; 104: 195-203.
• 89 Roos DCJ. Chronic granulomatous disease. In: Ochs HD SC, Puck JM. (ed). Primary immunodeficiency Diseases. Oxford University Press; 2007: 200-300.
• 90 Rupec RA, Petropoulou T, Belohradsky BH. et al. Lupus erythematosus tumidus and chronic discoid lupus erythematosus in carriers of X-linked chronic granulomatous disease. Eur J Dermatol 2000; 10: 184-189.
• 91 Schappi MG, Smith VV, Goldblatt D. et al. Colitis in chronic granulomatous disease. Arch Dis Child 2001; 84: 147-151.
• 92 Segal BH, Barnhart LA, Anderson VL. et al. Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin Infect Dis 2005; 40: 1684-688.
• 93 Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) 2000; 79: 170-200.
• 94 Segal BH, Steinbach WJ. Combination antifungals: an update. Expert review of anti-infective therapy 2007; 5: 883-892.
• 95 Seger RA, Gungor T, Belohradsky BH. et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985–2000. Blood 2002; 100: 4344-4350.
• 96 Shammas C, Menne TF, Hilcenko C. et al. Structural and mutational analysis of the SBDS protein family. Insight into the leukemia-associated Shwachman-Diamond Syndrome. The Journal of biological chemistry 2005; 280: 19221-19229.
• 97 Shimamura A. Shwachman-Diamond syndrome. Semin Hematol 2006; 43: 178-188.
• 98 Skokowa J, Germeshausen M, Zeidler C, Welte K. Severe congenital neutropenia: inheritance and pathophysiology. Current opinion in hematology 2007; 14: 22-28.
• 99 Stegmaier OC, Schneider LA. Chediak-Higashi Syndrome. Archives of dermatology 1965; 91: 1-9.
• 100 Steinbach WJ, Benjamin DK. New antifungal agents under development in children and neonates. Current opinion in infectious diseases 2005; 18: 484-489.
• 101 Stinchcombe JC, Page LJ, Griffiths GM. Secretory lysosome biogenesis in cytotoxic T lymphocytes from normal and Chediak Higashi syndrome patients. Traffic (Copenhagen, Denmark) 2000; 1: 435-444.
• 102 Swaminathan V, Kishore AH, Febitha KK, Kundu TK. Human histone chaperone nucleophosmin enhances acetylation-dependent chromatin transcription. Molecular and cellular biology 2005; 25: 7534-7545.
• 103 Thomas C, Le Deist F, Cavazzana-Calvo M. et al. Results of allogeneic bone marrow transplantation in patients with leukocyte adhesion deficiency. Blood 1995; 86: 1629-1635.
• 104 van Bruggen R, Bautista JM, Petropoulou T. et al. Deletion of leucine 61 in glucose-6-phosphate dehydrogenase leads to chronic nonspherocytic anemia, granulocyte dysfunction, and increased susceptibility to infections. Blood 2002; 100: 1026-1030.
• 105 Vulliamy T, Marrone A, Goldman F. et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 2001; 413: 432-435.
• 106 Walsh TJ, Lutsar I, Driscoll T. et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21: 240-248.
• 107 Walther MM, Malech H, Berman A. et al. The urological manifestations of chronic granulomatous disease. J Urol 1992; 147: 1314-1318.
• 108 Weiss MUW, Belohradsky BH. Systemische Pilzinfektionen. In: Reinhardt D. (ed). Therapie der Krankheiten im Kindes- und Jugendalter. Heidelberg: Springer; 2007: 453-461.
• 109 Welte K, Zeidler C, Dale DC. Severe congenital neutropenia. Semin Hematol 2006; 43: 189-195.
• 110 Wild MK, Luhn K, Marquardt T, Vestweber D. Leukocyte adhesion deficiency II: therapy and genetic defect. Cells, tissues, organs 2002; 172: 161-173.
• 111 Winkelstein JA, Marino MC, Johnston RB. Jr et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000; 79: 155-169.
• 112 Yabe M, Yabe H, Hattori K. et al. Fatal interstitial pulmonary disease in a patient with dyskeratosis congenita after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19: 389-392.
• 113 Yamauchi A, Yu L, Potgens AJ. et al. Location of the epitope for 7D5, a monoclonal antibody raised against human flavocytochrome b558, to the extracellular peptide portion of primate gp91phox. Microbiol Immunol 2001; 45: 249-257.
• 114 Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 2002; 168: 554-561.
• 115 Rocha V, Devergie A, Socié G. Unusual complications after bone marrow transplantation for dyskeratosis congenita. Br J Haematol 1998; 103 (01) 243-248.
• 116 Ghavamzadeh A, Alimoghadam K, Nasseri P. et al. Correction of bone marrow failure in dyskeratosis congenita by bone marrow transplantation. Bone Marrow Transplant 199 23 (03) 299-301.
• 117 Cossu F, Vulliamy TJ, Marrone A. et al. A novel DKC1 mutation, severe combined immunodeficiency (T+B-NK-SCID) and bone marrow transplantation in an infant with Hoyeraal-Hreidarsson syndrome. Br J Haematol 2002; 119 (03) 765-768.
• 118 Amarasinghe K, Dalley C, Dokal I. et al. Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan. Bone Marrow Transplant 2007; 40 (09) 913-914 Epub 2007 Aug 27. No abstract available.